ALLMedicine™ Heart Failure Center

Sep 18th, 2020 - Whether cardiovascular (CV) disease risk factors and biomarkers associate differentially with heart failure (HF) risk in men and women is unclear. The purpose of this study was to evaluate sex-specific associations of CV risk factors and biomarker...

Sep 18th, 2020 - We aimed to analyse the pathology of paravalvular leak (PVL), and determine the long-term outcomes of redo mitral valve replacement and risk factors of all-cause mortality. Seventy-nine patients (mean age 70 ± 9 years; 54 female, 68%) who underwen...

Sep 18th, 2020 - The purpose of this retrospective propensity score-matched study was to evaluate the superiority of different application approaches [continuous diuretics use (CDU) vs. intermittent diuretics use (IDU)] and types [loop diuretics (LDs) vs. thiazide...

Sep 18th, 2020 - Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to ...

Sep 18th, 2020 - Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant p...

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

Jun 16th, 2020 - 2019 AATS/ACC/SCAI/STS expert consensus systems of care document: Operator and institutional recommendations and requirements for transcatheter mitral valve intervention: A joint report of the American Association for Thoracic Surgery, the America...

Jun 4th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, ...

Apr 1st, 2020 - The latest news from the ACC Annual Scientific Session, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention, heart failure and more.

Mar 16th, 2020 - As the global impact of COVID-19 rises, the scientific community continues to evaluate the clinical impact and health care needs of patients with cardiovascular disease, who are at increased risk for serious complications with COVID-19. Together, ...

Sep 18th, 2020 - Whether cardiovascular (CV) disease risk factors and biomarkers associate differentially with heart failure (HF) risk in men and women is unclear. The purpose of this study was to evaluate sex-specific associations of CV risk factors and biomarker...

Sep 18th, 2020 - We aimed to analyse the pathology of paravalvular leak (PVL), and determine the long-term outcomes of redo mitral valve replacement and risk factors of all-cause mortality. Seventy-nine patients (mean age 70 ± 9 years; 54 female, 68%) who underwen...

Sep 18th, 2020 - The purpose of this retrospective propensity score-matched study was to evaluate the superiority of different application approaches [continuous diuretics use (CDU) vs. intermittent diuretics use (IDU)] and types [loop diuretics (LDs) vs. thiazide...

Sep 18th, 2020 - Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to ...

Sep 18th, 2020 - Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant p...

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

Jun 29th, 2020 - (Reuters) - The U.S. Food and Drug Administration on Monday approved Roche Holding AG’s combination therapy for a form of advanced breast cancer that has spread to other parts of the body. The therapy, Phesgo, was approved for patients with HER2-p...

Jun 1st, 2020 - (Reuters) - Abiomed Inc said on Monday the U.S. Food and Drug Administration has granted emergency use authorization for its temporary invasive heart pump to help patients suffering from COVID-19 related right heart failure. The device, Impella RP...

May 6th, 2020 - (Reuters) - AstraZeneca’s diabetes drug Farxiga has become the first in its class to win U.S. approval as a treatment for heart failure, opening up a major new market opportunity outside of the medicine’s established field. FILE PHOTO: The company...

Apr 1st, 2020 - The latest news from the ACC Annual Scientific Session, with physician perspective, researcher interviews and clinician insight on cardiovascular prevention, heart failure and more.